More recently, the company received an Established Inspection Report from the FDA which detailed more negative observations at the Srikakulam manufacturing site and will require corrective actions to be taken. While Dr. Reddy's is permitted to continue to distribute its pharmaceutical products to the US, the warning letter could impact the company's ability to get future approvals. The latest generic Lipitor recall follows a similar recall of over 80,000 bottles of atorvastatin in February of this year. The bottles were recalled over the same quality concerns, indicating Dr. Reddy's Srikakulam plant has plagued with the same manufacturing issues for months.